T cell replacement therapy - Kiadis Pharma

Drug Profile

T cell replacement therapy - Kiadis Pharma

Alternative Names: Allodepleted T-cell ImmunotheRapeutics; ATIR; ATIR-101; ATIR-201; ATIR101; Reviroc™; Rhitol™; T cell replacement therapy TH9402; TH-9402

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Montreal
  • Developer Kiadis Pharma
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Bone marrow transplant rejection; Transplant rejection; Follicular lymphoma; Graft-versus-host disease; B cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Graft-versus-host disease
  • Phase III Acute myeloid leukaemia
  • Phase II Acute lymphoblastic leukaemia; Bone marrow transplant rejection; Myelodysplastic syndromes
  • Phase I/II Beta-thalassaemia
  • Discontinued Chronic myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 10 Oct 2017 Kiadis Pharma plans a clinical trial for Graft-versus-host disease (Prevention, Combination therapy)
  • 20 Sep 2017 Kiadis Pharma expects to launch T cell replacement therapy for Graft-versus-host disease (Adjunctive treatment, Prevention) in European Union in 2019
  • 20 Sep 2017 T cell replacement therapy receives Regenerative Medicine Advanced Therapy designation from US FDA for Leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top